First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Three private biotechs enter clinical trials, one targeting KRAS.
The company will start three phase 3 trials of its G12D project this year.
But PFS data are lacking, and there are questions about first and second-line plans.
